Results 51 to 60 of about 18,058,309 (312)

A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

open access: yesBMC Infectious Diseases, 2020
Background A previous phase 2 study demonstrated the immunogenicity of a single dose of meningococcal A, C, W, Y-tetanus toxoid conjugate (MenACWY-TT) or polysaccharide (MenACWY-PS) vaccine for up to 5 years in individuals aged 11–55 years.
Charissa Fay Corazon Borja-Tabora   +10 more
doaj   +1 more source

Review of dengue virus and the development of a vaccine

open access: yes, 2011
[[abstract]]Dengue viral infection has become an increasing global health concern with over two-fifths of the world's population at risk of infection.
Murrell, S;Wu, SC;Butler, M
core   +1 more source

Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. [PDF]

open access: yes, 2012
BACKGROUND: Enterovirus 71 (EV71) has caused several epidemics of hand, foot and mouth diseases (HFMD) in Asia and now is being recognized as an important neurotropic virus.
Ai-Hsiang Chou   +36 more
core   +1 more source

The multifaceted roles of lysosomes in cancer

open access: yesMolecular Oncology, EarlyView.
Lysosomes support cancer cell adaptation by integrating macromolecule degradation and nutrient recycling with nutrient sensing, inter‐organelle communication and immune regulation. These interconnected functions can promote tumour growth, stress tolerance and therapy resistance, while also creating context‐dependent vulnerabilities that may be ...
Jia Li, Kevin M. Ryan
wiley   +1 more source

Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines

open access: yesnpj Vaccines
Seasonal epidemics of influenza viruses are responsible for a significant global public health burden. Vaccination remains the most effective way to prevent infection; however, due to the persistence of antigenic drift, vaccines must be updated annually.
Teresa Hauguel   +28 more
doaj   +1 more source

Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age

open access: yesHuman Vaccines & Immunotherapeutics, 2020
This phase 3B, open-label, extension study (NCT01962207) evaluated long-term persistence of antibodies induced by the quadrivalent meningococcal vaccine conjugated to tetanus toxoid (MenACWY-TT) compared with the meningococcal serogroup C vaccine ...
Timo Vesikari   +9 more
doaj   +1 more source

Malaria vaccine development [PDF]

open access: yesClinical Microbiology Reviews, 1994
The malaria parasite life cycle presents several targets for attack, but these different parts of the life cycle are susceptible to different types of host immune response. For example, the sporozoite is most sensitive to immune antibody, while liver stage parasites can be eliminated by cytotoxic T lymphocytes. Attachment of merozoites to erythrocytes,
T R, Jones, S L, Hoffman
openaire   +2 more sources

A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design

open access: yes, 2009
[[abstract]]We have developed a novel platform technology that can express high levels of recombinant lipoproteins with intrinsic adjuvant properties. In this study, Ag473 (a lipoprotein from Neisseria meningitidis) can be produced in high yields using ...
Chen, HW;Liu, SJ;Liu, HH;Kwok, Y;Lin, CL;Lin, LH;Chen, MY;Tsai, JP;Chang, LS;Chiu, FF;Lai, Lw;Lian, WC;Yang, CY;Hsieh, SY;Chong, P;Leng, CH
core   +1 more source

Immune potentiating effects of the HDAC inhibitor Zabadinostat on human immune and tumor cells

open access: yesMolecular Oncology, EarlyView.
Zabadinostat (CXD101) is a second‐generation class I histone deacetylase inhibitor (HDACi). We show that Zabadinostat activates human T cells and natural killer cells while reducing frequencies and function of regulatory T cells. Zabadinostat also increases T cell stemness and modulates tumor cell phenotype to potentially enhance immune recognition ...
Stephanie C. Pitts   +15 more
wiley   +1 more source

Modeling excess zeroes in an integrated analysis of vaccine safety

open access: yesHuman Vaccines & Immunotherapeutics, 2018
In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the ...
Roger Maansson   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy